Immuron Ltd ADR IMRN
Trading Information
- Previous Close Price
- $1.13
- Day Range
- $1.08–1.13
- 52-Week Range
- $0.68–2.39
- Bid/Ask
- $1.08 / $1.09
- Shares Outstanding
- 8.07M
- Market Cap
- $8.80M
- Volume/Avg
- 88,784 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.61
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 8
- Website
- https://www.immuron.com.au
Valuation
|
Metric
|
IMRN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.19 |
Price/Sales | 1.61 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IMRN
|
|---|---|
Quick Ratio | 5.84 |
Current Ratio | 7.26 |
Interest Coverage | −261.74 |
Quick Ratio
IMRN
Profitability
|
Metric
|
IMRN
|
|---|---|
Return on Assets (Normalized) | −27.78% |
Return on Equity (Normalized) | −33.04% |
Return on Invested Capital (Normalized) | −34.62% |
Return on Assets
IMRN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>x$Nhj | LOCK|SZ#^J | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?$#Nt?N | LOCK|>dwG# | $76B | |||
| Moderna Inc
MRNA
| LOCK|jcqVCJ | LOCK|rz | $75B | |||
| argenx SE ADR
ARGX
| LOCK|<>QJCg | LOCK|gz | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|##!XK@t | LOCK|k^ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>&T>$^> | LOCK|mw%np | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|gb!@hy#& | LOCK|$TNR< | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|XG%^YK | LOCK|$$n | $24B | |||
| Incyte Corp
INCY
| LOCK|D@r?Z% | LOCK|CZ@ | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#C^D^b | LOCK|X%& | $15B |
United States